Pictet Asset Management
MIRM icon

Pictet Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Pictet Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.1M Sell
423,511
-153,763
-27% -$14.5M 0.04% 361
2025
Q4 		$45.6M Buy
577,274
+35,997
+7% +$2.58M 0.04% 346
2025
Q3 		$39.7M Sell
541,277
-159,879
-23% -$10.2M 0.04% 366
2025
Q2 		$35.7M Sell
701,156
-77,088
-10% -$3.43M 0.04% 378
2025
Q1 		$35.1M Sell
778,244
-81,852
-10% -$3.86M 0.04% 374
2024
Q4 		$35.6M Sell
860,096
-35,594
-4% -$1.48M 0.04% 368
2024
Q3 		$34.9M Buy
895,690
+20,577
+2% +$821K 0.04% 362
2024
Q2 		$29.9M Sell
875,113
-80,801
-8% -$2.12M 0.03% 374
2024
Q1 		$24M Buy
955,914
+162,259
+20% +$4.46M 0.03% 459
2023
Q4 		$23.4M Buy
793,655
+54,645
+7% +$1.65M 0.03% 447
2023
Q3 		$23.4M Buy
+739,010
New +$20.2M 0.03% 418

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Pictet Asset Management's MIRM Position: Q1 2026 in Review

Pictet Asset Management reduced its Mirum Pharmaceuticals (MIRM) stake by 27% in Q1 2026, selling an estimated $14.5M and leaving 423,511 shares worth $39.1M. The position accounts for 0.04% of the portfolio, ranked #361.

Pictet Asset Management first reported a position in MIRM in Q3 2023 and has held it in 11 quarters since. The position peaked at $45.6M in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Pictet Asset Management held 423,511 shares of Mirum Pharmaceuticals worth $39.1M as of Q1 2026.
  • Pictet Asset Management sold 153,763 Mirum Pharmaceuticals shares in Q1 2026, an estimated $14.5M.
  • Mirum Pharmaceuticals made up 0.04% of Pictet Asset Management's portfolio in Q1 2026, its #361 holding.
  • Pictet Asset Management first reported a position in Mirum Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Mirum Pharmaceuticals position peaked at $45.6M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.